Recruiting × Endometrial Neoplasms × Genitourinary × Clear all A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors
Phase 1 Recruiting
214 enrolled
OMNIRAY
Phase 1 Recruiting
421 enrolled
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
Phase 2 Recruiting
89 enrolled
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Phase 1 Recruiting
80 enrolled
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
595 enrolled
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Phase 2 Recruiting
200 enrolled
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Phase 1 Recruiting
70 enrolled
panSOHO
Phase 2 Recruiting
111 enrolled
DP-04
Recruiting
100 enrolled
ERADIC8
Phase 1/2 Recruiting
120 enrolled
(CLOCS-2)
Recruiting
2,900 enrolled
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Phase 1 Recruiting
280 enrolled
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Phase 1 Recruiting
282 enrolled
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Phase 1/2 Recruiting
300 enrolled
PNeoVCA
Phase 1/2 Recruiting
132 enrolled
ELEPHAS-04
Recruiting
324 enrolled
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Phase 1 Recruiting
110 enrolled
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Phase 1 Recruiting
258 enrolled
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Phase 2 Recruiting
87 enrolled
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Phase 1/2 Recruiting
147 enrolled
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Phase 1 Recruiting
60 enrolled
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Phase 1 Recruiting
240 enrolled
Screening and Staging of Benign vs Malignant Pelvic Abnormalities
Recruiting
60 enrolled
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Phase 2 Recruiting
520 enrolled
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
216 enrolled
A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
250 enrolled
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase 2 Recruiting
740 enrolled
iCaRe2
Recruiting
999,999 enrolled
CAMPERR
Recruiting
7,000 enrolled
A Study of DM002 in Patients With Advanced Solid Tumors
Phase 1 Recruiting
160 enrolled
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
Phase 1 Recruiting
43 enrolled
Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial
Phase NA Recruiting
50 enrolled
ELEPHAS-05
Recruiting
2,000 enrolled
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Phase 1 Recruiting
96 enrolled
ELEPHAS-02
Recruiting
416 enrolled
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Phase 2 Recruiting
27 enrolled
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Phase 1 Recruiting
130 enrolled
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Phase 1/2 Recruiting
27 enrolled
Trop2-targeted immunoPET Imaging of Solid Tumors
Phase 2/3 Recruiting
400 enrolled
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
Phase 1 Recruiting
10 enrolled
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Recruiting
50,000 enrolled
ORACLE
Recruiting
2,020 enrolled
TTBF
Phase NA Recruiting
1,000 enrolled
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors
Phase 1 Recruiting
241 enrolled
ABILITY-1
Phase 1/2 Recruiting
115 enrolled
START-001
Phase 1/2 Recruiting
365 enrolled
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
115 enrolled
MOIO
Phase 3 Recruiting
646 enrolled
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Phase 1/2 Recruiting
275 enrolled
ADPORT-601
Phase 1/2 Recruiting
90 enrolled